|
Monday, July 12, 2021, 5:00 PM – 6:00 PM Eastern Time (ET)
A Conversation with the Investigators: Hormonal Therapy for Prostate CancerA Live CME/MOC Webinar Held Adjunct to the 2021 ASCO Annual MeetingJoin us on Monday, July 12th for this CME/MOC-accredited webinar Faculty
Simon Chowdhury, MD, PhD
Consultant Medical Oncologist London, United Kingdom Tanya B Dorff, MD Associate Clinical Professor of Medicine City of Hope National Medical Center Department of Medical Oncology and Developmental Therapeutics Head, Genitourinary Cancer Program Los Angeles, California
Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers Professor of Medicine, Harvard Medical School Director, Genitourinary Malignancies Program Massachusetts General Hospital Cancer Center Boston, Massachusetts Moderator Neil Love, MD Research To Practice Miami, Florida Optimal Integration of Androgen Receptor-Targeted Therapy into the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer (CRPC)
Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Target Audience Learning Objectives
CME Credit Form Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Disclosure Policy FACULTY — Dr Chowdhury has no relevant conflicts of interest to disclose. The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process: Dr Dorff — Advisory Committee: AbbVie Inc, Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Janssen Biotech Inc; Consulting Agreements: Dendreon Pharmaceuticals Inc, Janssen Biotech Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Pfizer Inc. Dr Smith — Advisory Committee and Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |